恒瑞医药(600276.SH):HRS-2261片获批开展临床试验
格隆汇3月1日丨恒瑞医药(600276.SH)公布,近日,公司子公司广东恒瑞医药有限公司、成都盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于HRS-2261片的《药物临床试验批准通知书》,将于近期开展临床试验。
根据《中华人民共和国药品管理法》及有关规定,经审查,2021年12月13日受理的HRS-2261片符合药品注册的有关要求,同意本品开展慢性咳嗽的临床试验。
HRS-2261片拟用于治疗慢性咳嗽。经查询,目前国内尚无同类产品获批上市,亦无相关销售数据。截至目前,HRS-2261相关研发项目累计已投入研发费用约519万元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.